CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma

Cytometry Part B - Clinical Cytometry

Volumn 82 B, Issue 2, 2012, Pages 112-119

  Dakappagari, Naveen ^a   Ho, Steffan N ^a   Gascoyne, Randy D ^b   Ranuio, Julie ^c   Weng, Andrew P ^b   Tangri, Shabnam ^d  

^a PFIZER INC   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c BIOGEN   (United States)

^d Genoptix Inc   (United States)

Author keywords

B cells; CD80; flow cytometry; non Hodgkin lymphoma; T cells

Indexed keywords

B7 ANTIGEN;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL SUSPENSION; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA CELL; T LYMPHOCYTE; TUMOR BIOPSY;

ANTIGENS, CD80; B-LYMPHOCYTES; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; LYMPHOMA, NON-HODGKIN; STROMAL CELLS; T-LYMPHOCYTES;

EID: 84857366162     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20631     Document Type: Article

References (19)

1. Azuma M, Yssel H, Phillips JH, Spits H, Lanier LL,. Functional expression of B7/BB1 on activated T lymphocytes. J Exp Med 1993; 177: 845-850. (Pubitemid 23104296)
2. Greenwald RJ, Freeman GJ, Sharpe AH,. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548. (Pubitemid 40563179)
3. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R,. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70: 4335-4345.
4. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562-567. (Pubitemid 36597102)
5. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ,. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2010; 27: 111-122. (Pubitemid 47089023)
6. Butte MJ, Pena-Cruz V, Kim MJ, Freeman GJ, Sharpe AH,. Interaction of human PD-L1 and B7-1. Mol Immunol 2008; 45: 3567-3572.
7. Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, Yao S, Tsushima F, Narazaki H, Anand S, et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116: 1291-1298.
8. Dogan A, Du MQ, Aiello A, Diss TC, Ye HT, Pan LX, Isaacson PG,. Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone. Blood 1998; 91: 4708-4714. (Pubitemid 28270321)
9. Dorfman DM, Schultze JL, Shahsafaei A, Michalak S, Gribben JG, Freeman GJ, Pinkus GS, Nadler LM,. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997; 90: 4297-4306. (Pubitemid 27508435)
10. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM,. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83: 793-798.
11. Vyth-Dreese FA, Boot H, Dellemijn TA, Majoor DM, Oomen LC, Laman JD, Van Meurs M, De Weger RA, De Jong D,. Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 1998; 94: 580-586. (Pubitemid 28352799)
12. Chaperot L, Plumas J, Jacob MC, Bost F, Molens JP, Sotto JJ, Bensa JC,. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp Hematol 1999; 27: 479-488. (Pubitemid 29125056)
13. Bence-Bruckler I, Stiff PJ, McKinney B, Ruffner KL, Wilson L, Whiteley M, Kahl B,. A phase 2, double-blind, placebo-controlled trial of Rituximab + Galiximab vs Rituximab + placebo in advanced follicular non-Hodgkin's lymphoma (NHL), in 52nd ASH Annual Meeting and Exposition, Orlando, FL; 2010.
14. Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005; 23: 4390-4398. (Pubitemid 46207013)
15. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511. (Pubitemid 30082188)
16. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 2159-2169. (Pubitemid 39507628)
17. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
18. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. (Pubitemid 34651353)
19. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, Klasa R, Voss N, Connors JM, Gascoyne RD,. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 2169-2174. (Pubitemid 41291735)